Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
In this study, 24 adult patients with head lice will be treated with a topical malathion head
lice treatment; 12 patients will be treated with a novel product, Malathion Gel, 0.5%, and
other 12 patients will be treated with Ovide Lotion 0.5% marketed by Taro Pharmaceuticals
USA, Inc. The primary objective of this study is to compare the blood level exposure of
Malathion 0.5% Gel to that of the OVIDE Lotion 0.5%.